Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ 01/07/96 \ \ Origin: Appendix \ 5 \ \ Amended \ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13$

Name of	entity	
	fe Sciences Ltd	
ABN		
	3 190 421	
We (th	e entity) give ASX the following i	nformation.
	1 - All issues t complete the relevant sections (attach s	heets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,000,000 ordinary shares
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary shares subject to restrictions in accordance with the Company's Long Term Incentive Plan (LTIP) shares. Refer to Annexure 2 for details.

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$900,000 (refer to Annexure 2)
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Plan shares issued under the terms of the Company's LTIP via a limited recourse loan provided by the Company as approved. Refer to Annexure 2 for details.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
		[
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	+1	20 May 2010	
,	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	30 May 2018	
	Cross reference: item 33 of Appendix 3B.		
		Number	⁺ Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	54,842,257	Ordinary

⁺ See chapter 19 for defined terms.

	_		
		Number	+Class
9	Number and +class of all	Nil	N/A
	+securities not quoted on ASX (including the +securities in		
	section 2 if applicable)		
4.0	D	71 1	1. 1
10	Dividend policy (in the case of a trust, distribution policy) on the	Identical to existing or	dinary shares
	increased capital (interests)		
Part 2	2 - Pro rata issue		
11	Is security holder approval	N/A	
11	required?	N/A	
12	Is the issue renounceable or non-	N/A	
	renounceable?	,	
13	Ratio in which the ⁺ securities will	N/A	1
	be offered	11/11	
14	⁺ Class of ⁺ securities to which the	NI / A	
14	offer relates	N/A	
15	15 1 1 · · · · · · · · · · · · · · · · ·	N1 / A	
15	⁺ Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be	N/A	
	aggregated for calculating		
	entitlements?		
17	Policy for deciding entitlements in	N/A	
	relation to fractions		
18	Names of countries in which the	N/A	
	entity has security holders who will not be sent new offer		
	documents		
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.		
19	Closing date for receipt of	N/A	
1)	acceptances or renunciations	IV/A	

⁺ See chapter 19 for defined terms.

Appendix 3B Page 4 04/03/2013

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	⁺ Issue	e date	N/A
		uotation of securiti	
34	Type (tick o	of ⁺ securities one)	
(a)		⁺ Securities described in Part	1
(b)			nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entitie	s tha	t have ticked box 34(a)	
Additio	onal s	ecurities forming a new c	lass of securities
Tick to docume		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36			r securities, a distribution schedule of the additional amber of holders in the categories
37		A copy of any trust deed for	the additional ⁺ securities

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Entitie	s that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 30 May 2018

(Company secretary)

Print name: Chin L Khoo

== == == ==

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Not Applicable

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 2

Description	No of Plan Shares	Value-\$
Plan shares with an exercise price of \$0.80 per share,	500,000	400,000
exercisable upon meeting certain cumulative EBIT of the Group		
for the two financial years ending 31 Dec 2018 and 31 Dec		
2019, expiring on 30 Jun 2020		
Plan shares with an exercise price of \$1.00 per share,	500,000	500,000
exercisable upon meeting certain cumulative EBIT of the Group		
for the two financial years ending 31 Dec 2019 and 31 Dec		
2020, expiring on 30 Jun 2021		
Total Plan Shares issued to Mr Andrew O'Keefe	1,000,000	900,000

Total Plan Shares issued to Director on 30 May 2018	1,000,000	\$900,000

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.